Effectiveness of pentavalent rotavirus vaccine — a propensity score matched test negative design case-control study using electronic health records in three provinces of China

Yuexin Xiu, Lin Tang, Fuzhen Wang, Lei Wang, Zhen Li, Jun Liu, Dan Li, Xueyan Li, Yi Yao, Fan Zhang, Yu Lei, Jingfeng Wu, Zundong YinResearch Square 2025 · DOI

Abstract

Rotavirus remains a leading cause of severe gastroenteritis in young children globally. This study evaluated the real-world vaccine effectiveness (VE) of the live oral pentavalent rotavirus vaccine (RV5, RotaTeq) in China using a propensity score matched test-negative design. Analyzing data from over 27,000 children across three provinces, the study found that a complete three-dose series provides significant protection (67.2%) against medically attended rotavirus gastroenteritis (RVGE). Notably, the vaccine demonstrated a severity gradient, with higher effectiveness against hospitalizations (69.4%) compared to outpatient visits (57.5%). Protection remained robust, staying above 61% for over a year following the final dose.

Introduction

Rotavirus is the primary cause of severe, dehydrating diarrhea in infants and young children. In China, the pentavalent rotavirus vaccine (RV5) was licensed in 2018, offering a critical intervention for pediatric health. However, previous evaluations of its effectiveness in the Chinese population were often limited by small sample sizes or regional focus. This study leverages large-scale electronic health records (EHR) and person-matched immunization registries from three diverse provinces—Guangdong, Beijing, and Hubei—to provide a comprehensive evaluation of RV5's performance in a real-world setting between 2020 and 2024.

Methods

The researchers employed a test-negative design (TND), a gold-standard observational method that compares vaccination status between patients testing positive for a target pathogen (cases) and those testing negative (controls) among individuals seeking care for similar symptoms. This approach naturally controls for healthcare-seeking behavior.

Data were integrated from 29 hospitals and provincial immunization information systems, covering 27,472 children aged 8 weeks to 4 years who presented with acute gastroenteritis (AGE). To minimize confounding bias, propensity score matching (PSM) was used to match each rotavirus-positive case with two rotavirus-negative controls based on age, month of clinical visit, and province. Vaccine effectiveness was calculated as (1 - Odds Ratio) × 100% using logistic regression.

Results

Among the study population, 7.98% (2,192) of children tested positive for rotavirus. The analysis revealed several key insights into the vaccine's performance:

Dose-Response and Overall Effectiveness

A full three-dose series of RV5 was significantly more effective than a partial series. The VE for 1–2 doses was 57.6% (95% CI: 39.8%–70.2%), while the VE for the complete 3-dose series reached 67.2% (95% CI: 60.3%–72.9%). This reinforces the importance of completing the full vaccination schedule.

The Severity Gradient

The vaccine demonstrated a clear "severity gradient," offering greater protection against more severe clinical outcomes. The 3-dose VE against RVGE-related hospitalization was 69.4% (95% CI: 41.3%–84.0%), whereas the VE against outpatient-only visits was 57.5% (95% CI: 38.9%–70.5%).

Persistence of Protection

Protection remained stable over time. For children who completed the series, the VE was 70.4% within five months of the last dose. Even more than a year after vaccination, the VE remained above 61%. This suggests that RV5 provides durable immunity during the most vulnerable years of early childhood.

Discussion

These findings confirm that RV5 is a highly effective tool for reducing the burden of rotavirus in China, consistent with international data. The study also highlights the utility of using integrated big data—EHR and immunization registries—for rapid, large-scale public health monitoring.

While the study did not include viral genotyping, the results suggest that RV5 likely provides cross-protection against circulating strains in China, including emerging genotypes like G8. The high effectiveness against hospitalization is particularly important for reducing the economic and healthcare burden associated with severe rotavirus infections.

Limitations

The study's reliance on data from major urban hospitals may introduce an urban bias, as rotavirus vaccine coverage is currently lower in rural China. Additionally, the researchers used hospitalization as a proxy for disease severity rather than clinical scoring systems like the Vesikari scale. Future research will focus on long-term duration of protection (3–5 years post-vaccination) and the vaccine's impact on specific circulating genotypes.

Conclusion

The pentavalent rotavirus vaccine is highly effective in preventing medically attended rotavirus gastroenteritis among children under five in China. Public health efforts should continue to emphasize the completion of the three-dose series to maximize protection against severe disease and hospitalization.

Summary updated

Abstract

<title>Abstract</title> Background. Our study aimed to evaluate vaccine effectiveness (VE) of a live oral pentavalent rotavirus vaccine (RotaTeq, RV5) among &lt; 5-year-old children in three provinces of China via a propensity score matched test negative design case-control study. Methods. We used electronic health records and person-matched immunization information system data to obtain information on acute gastroenteritis (AGE) cases in Guangdong, Beijing, and Hubei provinces evaluated for AGE in emergency department settings and tested for rotavirus (RV) infection during 2020–2024. RV positive cases were propensity-score matched with RV negative subjects on age, visit month, and province. Primary outcomes were medically-attended RVGE infection (inpatient or outpatient), outpatient-only medically-attended RVGE, and RVGE hospitalization. VE was estimated with logistic regression as (1-OR)×100%. Results. The study included 27 472 children with AGE aged 8 weeks to 4 years at the time of the visit; 7.98% (2 192) were rotavirus positive. After propensity score matching of 2 controls for each case, VE (95% confidence interval, <italic>CI</italic>) of 1–2 and 3 doses of RV5 against infection were 57.6% (39.8%, 70.2%) and 67.2% (60.3%, 72.9%), respectively. Among children who received a third dose &lt; 5-months-old, 3-dose VE decreased from 70.4% (53.9%, 81.1%) (&lt; 5 months) to 65.4% (49.8%, 76.1%) (5 months - &lt;1 year), and to 63.0% (49.1%, 73.0%) (≥ 1 year). Among children who received a third dose ≥ 5-months-old, 3-dose VE decreased from 69.3% (45.9%, 82.6%) (&lt; 5 months) to 61.7% (44.2%, 73.8%) (≥ 1 year). Three-dose VE was 69.4% (41.3%, 84.0%) against hospitalization and 57.5% (38.9%, 70.5%) against outpatient RVGE. Conclusions. Three doses of RV5 provided highest protection against RVGE among &lt; 5-year-old children. Three-dose VE decreased by time since the third dose in children who received a third dose at &lt; 5-months-olds, and remained &gt; 61% ≥1 year after the third dose. VE was higher against RVGE hospitalization than outpatient RVGE.
BibTeX
@inproceedings{xiu2025effectiveness,
  author = {Yuexin Xiu and Lin Tang and Fuzhen Wang and Lei Wang and Zhen Li and Jun Liu and Dan Li and Xueyan Li and Yi Yao and Fan Zhang and Yu Lei and Jingfeng Wu and Zundong Yin},
  title = {{Effectiveness of pentavalent rotavirus vaccine — a propensity score matched test negative design case-control study using electronic health records in three provinces of China}},
  booktitle = {Research Square},
  year = {2025},
  doi = {10.21203/rs.3.rs-5792504/v1},
}
Figure